Entero Therapeutics, Inc.
ENTO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.06 | 0.02 | -0.00 |
| FCF Yield | -10.36% | -0.96% | -11.93% | -1.93% |
| EV / EBITDA | -7.04 | -10.25 | -8.21 | -7.37 |
| Quality | ||||
| ROIC | -0.91% | -1.14% | -1.43% | -20.52% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.74 | 0.05 | 0.65 | 0.01 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -1,459.26% | 93.30% | -377.29% | 90.72% |
| Safety | ||||
| Net Debt / EBITDA | 1.80 | -1.30 | -0.83 | 0.02 |
| Interest Coverage | -25.92 | -17.71 | -45.88 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |